Company news

Solid Biosciences Inc. news in 2026

Solid Biosciences Inc.'s news releases, calls and decks from 2026, newest first.

View company

Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia

October 26, 2026

Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026

October 20, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics

June 2, 2026

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 12, 2026

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

May 7, 2026

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

April 30, 2026

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

April 27, 2026

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 18, 2026

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

March 10, 2026

Solid Biosciences Announces Oversubscribed $240 Million Private Placement

March 5, 2026

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

February 9, 2026

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

February 6, 2026

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

January 13, 2026

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

January 12, 2026

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

January 12, 2026

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 6, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 5, 2026

Decks in 2026